Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection

April 25, 2022

By Sara Hurvitz, MD
Stefania Maraka, MD

Video

Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.

EP: 1.Clinical Case Presentation: A 36-Year-Old Woman with Breast Cancer and Brain Metastases

EP: 2.Treatment Options in the Frontline Setting for Metastatic HER2+ Breast Cancer

EP: 3.Second-Line and Third-Line Treatment Options for Metastatic HER2+ Breast Cancer

Now Viewing

EP: 4.Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection

EP: 5.Treatment Options for HER2+ Breast Cancer After Progression on Tucatinib

EP: 6.Clinical Case Presentation: A 53-Year-Old Woman with Metastatic ER/PR+ HER2+ Breast Cancer and Brain Metastases

EP: 7.Neratinib for Metastatic HER2+ Breast Cancer and Brain Metastases

EP: 8.Leptomeningeal Metastases in HER2+ Breast Cancer

EP: 9.Novel Agents Under Evaluation for HER2+ Breast Cancer and Brain Metastases

EP: 10.Clinical Case Presentation: A 66-Year-Old Woman with ER+ HER2+ Invasive Ductal Carcinoma and Brain Metastases

EP: 11.Trastuzumab Deruxtecan Treatment for Metastatic HER2+ Breast Cancer with Brain Metastases

EP: 12.Role of Neurooncologists in Management of HER2+ Breast Cancer and Brain Metastases

EP: 13.Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!